Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Movement Disorders

Volumn 28, Issue 2, 2013, Pages 131-144

  Kalia, Lorraine V ^a,b   Brotchie, Jonathan M ^c   Fox, Susan H ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AQW 051; CAFFEINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FAMOTIDINE; GLUTAMATE DECARBOXYLASE; HISTAMINE H2 RECEPTOR ANTAGONIST; ISTRADEFYLLINE; MEMANTINE; METABOTROPIC RECEPTOR ANTAGONIST; METHYLPHENIDATE; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; NICOTINE; NICOTINIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NP 002; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; PRELADENANT; RIVASTIGMINE; SAFINAMIDE; SEROTONIN 1A AGONIST; TALAMPANEL; TOZADENANT; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 81444; VIPADENANT;

ARTICLE; CHOLINERGIC SYSTEM; CLINICAL FEATURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSKINESIA; FALLING; GAIT; GAIT DISORDER; HUMAN; LEWY BODY; LONG TERM CARE; MEYNERT BASAL NUCLEUS; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA AND VOMITING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STABILOGRAPHY; STRIATONIGRAL DEGENERATION; VIRAL GENE THERAPY;

ACETYLCHOLINE; ADENOSINE A3 RECEPTOR ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIPARKINSON AGENTS; CAFFEINE; CHOLINESTERASE INHIBITORS; GABA MODULATORS; GENETIC THERAPY; GLUTAMATE DECARBOXYLASE; HISTAMINE H2 ANTAGONISTS; HUMANS; MOVEMENT DISORDERS; NICOTINIC AGONISTS; PARKINSON DISEASE; PHOSPHODIESTERASE INHIBITORS; RECEPTOR, ADENOSINE A2A; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN RECEPTOR AGONISTS;

EID: 84874216826     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25273     Document Type: Article

References (114)

1. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
2. Whitehouse PJ, Hedreen JC, White CL, 3rdPrice DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983;13:243-248.
3. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A 1987;84:5976-5980.
4. Karachi C, Grabli D, Bernard FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 2010;120:2745-2754.
5. Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord 2011;26:2496-2503.
6. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26( Suppl 3):S42-S80.
7. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010;75:1263-1269.
8. Kareus S. A randomized, double-blind, placebo controlled, crossover study to evaluate the effect of donepezil on gait and balance in Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD: National Library of Medicine (US); 2000 [cited 2012 Jul 16]. Available at: http://clinicaltrials.gov/show/NCT01521117.
9. Oregon Health and Science University. A randomized, double-blind, placebo controlled, crossover study to evaluate the effect of donepezil on gait and balance in Parkinson's disease. Fox Trial Finder [internet]. New York, NY:The Michael J. Fox Foundation for Parkinson's Research;2011[cited 2012 Jul16]. Available at: http://foxtrialfinder.michaeljfox.org/trial/2684.
10. Kareus SA, Lai A, Horak FB, Nutt JG, Chung KA. The effect of donepezil on a quantitative measure of balance in Parkinson's disease. Mov Disord 2012;27( Suppl 1):S123.
11. Whone A. Phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. Fox Trial Finder [internet]. New York, NY: The Michael J. Fox Foundation for Parkinson's Research; 2011 [cited 2012 Jul 16]. Available at: http://foxtrialfinder.michaeljfox.org/trial/2641.
12. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002;53:590-605.
13. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord 2008;23:1641-1652.
14. Ebersbach G, Stöck M, Müller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 1999;14:1011-1013.
15. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn 2000;43:274-282.
16. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001;57:1032-1035.
17. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:31-39.
18. Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 2007;14:1313-1316.
19. Itti E, Villafane G, Malek Z, et al. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. Nucl Med Commun 2009;30:513-518.
20. Cesaro P. Efficacy of transdermal nicotine, on motor symptoms in advanced Parkinson's disease (one daily administration). A controlled randomised study, in two parallel groups and single blind in 40 patients. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 16]. Available at: http://clinicaltrials.gov/show/NCT00873392.
21. Boyd J, Oertel W. A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 16]. Available at: http://clinicaltrials.gov/show/NCT01560754.
22. Bordia T, Campos C, Huang L, Quik M. Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008;327:239-247.
23. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62:588-596.
24. Bordia T, Campos C, McIntosh JM, Quik M. Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 2010;333:929-938.
25. Neuraltus Pharmaceuticals, Inc.Randomized, double-blind, parallel group, placebo controlled safety, tolerability and efficacy study of NP002 in subjects with idiopathic Parkinson's disease with dyskinesias due to levodopa therapy. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 16]. Available at: http://clinicaltrials.gov/show/NCT00957918.
26. Lieberman A; np002 Study Investigators. Safety, tolerability, and preliminary efficacy of NP002 for levodopa-induced dyskinesias (LIDS) in Parkinson's disease (PD) patients. Mov Disord 2011;26( Suppl 2):S258.
27. Novartis Pharmaceuticals. A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson's patients with moderate to severe L-dopa induced dyskinesias. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 16]. Available at: http://clinicaltrials.gov/show/NCT01474421.
28. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
29. Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 2003;184:285-294.
30. Armentero MT, Pinna A, Ferré S, Lanciego JL, Müller CE, Franco R. Past, present, and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther 2011;132:280-299.
31. Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Ann Neurol 2012;71:278-282.
32. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-296.
33. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
34. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70:2233-2240.
35. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302.
36. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010;25:1437-1443.
37. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008;23:2177-2185.
38. Mizuno Y, Kondo T. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study. Mov Disord 2012;27( Suppl 1):S129.
39. Factor S, Mark MH, Watts R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord 2010;16:423-426.
40. Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 2010;16:16-20.
41. Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 2012;13:111-114.
42. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011;10:221-229.
43. Merck. A phase 2, 12-week, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy and safety of preladenant in Japanese subjects with moderate to severe Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01294800.
44. Merck. A phase 3, 12-week, double-blind, double-dummy, placebo- and active-controlled efficacy and safety study of preladenant in subjects with moderate to severe Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01155466.
45. Merck. A phase 3, 12-week, double-blind, placebo-controlled efficacy and safety study of preladenant in subjects with moderate to severe Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01227265.
46. Merck. An active-controlled extension study to P04938 and P07037. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01215227.
47. Merck. A phase 3, double-blind, double-dummy, placebo- and active-controlled dose-range-finding efficacy and safety study of preladenant in subjects with early Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01155479.
48. Biotie Therapies Inc. A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson's subjects with end of dose wearing off. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01283594.
49. Black KJ, Koller JM, Campbell MC, Gusnard DA, Bandak SI. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci 2010;30:16284-16292.
50. Biogen Idec. A randomized, double-blind, placebo-controlled, dose escalation study of multiple doses of BIIB014 administered orally in subjects with early Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Aug 8]. Available at: http://clinicaltrials.gov/show/NCT00442780.
51. Biogen Idec. A randomized, double-blind, placebo-controlled, dose escalation study of multiple oral dose administration of BIIB014 in subjects with early Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Aug 8]. Available at: http://clinicaltrials.gov/show/NCT00451815.
52. Biogen Idec. A randomized, double-blind, placebo-controlled, dose escalation study of single and multiple oral dose administration of BIIB014 in subjects with moderate to late stage Parkinson's disease who are also receiving treatment with levodopa. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Aug 8]. Available at: http://clinicaltrials.gov/show/NCT00438607.
53. Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson's disease. Mov Disord 2007;22:710-712.
54. Altman RD, Lang AE, Postuma RB. Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord 2011;26:2427-2431.
55. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-658.
56. Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002;298:425-429.
57. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309-319.
58. Neurologix, Inc. Long term follow-up study for rAAV-GAD treated subjects. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01301573.
59. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991;48:977-981.
60. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005;20:919-931.
61. Addy C, Assaid C, Hreniuk D, et al. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol 2009;49:856-864.
62. Nutt JG, Gunzler SA, Kirchhoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101, 606, on dyskinesia and Parkinsonism. Mov Disord 2008;23:1860-1866.
63. Hanaǧasi HA, Kaptanoglu G, Sahin HA, Emre M. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa. Mov Disord 2000;15:1016-1017.
64. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov Disord 2010;25:508-510.
65. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999;22:273-276.
66. Devos D. Study of memantine to treat gait disorders and attention deficit in Parkinson's disease: a randomized, double-blind, placebo-controlled, parallel-group, monocentric trial. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01108029.
67. Moreau C, Delval A, Dujardin K, et al. Memantine for gait disorders, axial rigidity and attention deficit in Parkinson's disease? A double blind placebo controlled study. Mov Disord 2011;26( Suppl 2):S257.
68. Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 2012;27:284-288.
69. Teva Pharmaceutical Industries. Effects of talampanel on patients with advanced Parkinson's disease who have been on sinemet for more than 5 years and have dyskinesia. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited Jul 20]. Available at: http://clinicaltrials.gov/show/NCT00036296.
70. National Institute of Neurological Disorders and Stroke (NINDS). AMPA receptor antagonist treatment of Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT00108667.
71. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6:787-798.
72. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-1250.
73. Kumar R, Hauser RA, Mostillo J, Dronamraju N, Graf A, Merschhemke M. A 6-week, double-blind, multicenter RCT in Parkinson's disease patients to explore the efficacy and safety of AFQ056 when combined with increased doses of L-dopa. Mov Disord 2012;27( Suppl 1):S126.
74. Novartis Pharmaceuticals. 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01491529.
75. Addex Pharma S.A. Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01336088.
76. Tison F, Durif F, Corvol JC, et al. Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinson's disease (PD) patients with levodopa-induced dyskinesia (LID). Poster session presented at: Late-Breaking Abstracts. 16th International Congress of Parkinson's Disease and Movement Disorders; 2012 June 17-21; Dublin, Ireland.
77. Johnston TH, van der Meij A, Brotchie JM, Fox SH. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease. Mov Disord 2010;25:1379-1390.
78. Fox S. Famotidine for the treatment of levodopa-induced dyskinesia: an "N-of-1" Study. Fox Trial Finder [internet]. New York, NY:The Michael J. Fox Foundation for Parkinson's Research;2011 [cited 2012 Jul 20]. Available at: http://foxtrialfinder.michaeljfox.org/trial/2666.
79. Shah BB, Connolly B, Mestre TA, et al. Famotidine for the treatment of levodopa-induced dyskinesia: an ongoing "'N-of-1'" Study. Mov Disord 2012;27:e4.
80. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-1331.
81. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004;55:766-773.
82. Salatino-Oliveira A, Genro JP, Zeni C, et al. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;70:216-221.
83. Auriel E, Hausdorff JM, Herman T, Simon ES, Giladi N. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin Neuropharmacol 2006;29:15-17.
84. Pollak L, Dobronevsky Y, Prohorov T, Bahunker S, Rabey JM. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neural Transm Suppl 2007;(72):145-148.
85. Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:470-475.
86. Espay AJ, Dwivedi AK, Payne M, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011;76:1256-1262.
87. Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-596.
88. Pourcher E. Two-phase Randomized controlled trial of low and moderate dose methylphenidate for non-motor and postural symptoms in Parkinson's disease. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01244269.
89. Lewitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79:163-169.
90. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008;108:1614-1641.
91. Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011;95:163-212.
92. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179-186.
93. Huot P, Fox SH, Newman-Tancredi A, Brotchie JM. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? J Pharmacol Exp Ther 2011;339:2-8.
94. Hauser RA, Gertner JM, Okamoto M, Reed RF, Sage JI. Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications. Parkinsonism Relat Disord 2009;15( Suppl 2):S118.
95. Sage JI, Hauser RA, Cordon ME, et al. Pilot study of the efficacy and safety of piclozotan in Parkinson's disease patients with L-dopa induced motor complications. Mov Disord 2009;24( Suppl 1):S277.
96. Bronzova J, Sampaio C, Hauser RA, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 2010;25:738-746.
97. Sampaio C, Bronzova J, Hauser RA, et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord 2011;26:1464-1476.
98. Rascol O, Bronzova J, Hauser RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012;18:370-376.
99. Rascol O, Poewe W, Lees A, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008;65:577-583.
100. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring) 2008;16:1363-1369.
101. Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003;18:1301-1305.
102. Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004;485:159-164.
103. Hill MP, Ravenscroft P, Bezard E, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:386-394.
104. Wolz M, Löhle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm 2010;117:1279-1286.
105. Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2011;26:264-270.
106. Wong KK, Alty JE, Goy AG, Raghav S, Reutens DC, Kempster PA. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Mov Disord 2011;26:1552-1555.
107. Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 2006;29:148-153.
108. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2005;20:1205-1209.
109. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001;41:397-399.
110. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68:45-50.
111. Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012;27:106-112.
112. EMD Serono. A phase iii, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson's disease treated with a stable dose of a single dopamine agonist. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT00605683.
113. Merck KGaA. A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced Dyskinesias. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT01113320.
114. EMD Serono. A Phase iii, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. ClinicalTrials.gov [internet]. Bethesda, MD:National Library of Medicine (US);2000 [cited 2012 Jul 20]. Available at: http://clinicaltrials.gov/show/NCT00627640.